Research programme: anti-infectives - Triad Therapeutics

Drug Profile

Research programme: anti-infectives - Triad Therapeutics

Alternative Names: EACPR inhibitors - Triad Therapeutics; Oxidoreductase inhibitors - Triad Therapeutics/Schering-Plough

Latest Information Update: 01 Mar 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Schering-Plough; Triad Therapeutics
  • Class
  • Mechanism of Action Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Methicillin-resistant Staphylococcus aureus infections; Mycoses

Most Recent Events

  • 10 Dec 2004 Triad Therapeutics is ceasing operations and selling its assets
  • 27 Aug 2003 Preclinical trials in Methicillin-resistant Staphylococcus aureus infections in USA (unspecified route)
  • 27 Aug 2003 Preclinical trials in Mycoses in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top